VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
VERTEX PHARMACEUTICALS INC / MA revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $12.59B | $12.20B | $11.97B | $11.69B | $11.39B | $11.09B | $11.02B | – | – | – | – | – | 100.0% | +10.5% |
| TRIKAFTA/KAFTRIO | $10.08B | $10.13B | $10.31B | $10.46B | $10.39B | $10.29B | $10.24B | $9.85B | $9.54B | $9.33B | $8.94B | $8.63B | 80.1% | -3.0% |
| ALYFTREK | $1.63B | $1.21B | $837.80M | $457.70M | $210.70M | $53.90M | $0 | – | – | – | – | – | 12.9% | +671.3% |
| Other CF product revenues | $686.20M | $742.80M | $820.10M | $716.00M | $727.10M | $729.80M | $781.50M | $774.70M | $797.00M | – | $924.50M | – | 5.5% | -5.6% |
| CASGEVY | $190.50M | $144.50M | $115.80M | $69.50M | $54.60M | $24.20M | $10.00M | – | – | – | – | – | 1.5% | +248.9% |
| JOURNAVX | $124.90M | $87.30M | $59.60M | $32.90M | $13.30M | $1.30M | $0 | – | – | – | – | – | 1.0% | +839.1% |
| Other revenues | $0 | $20.70M | $30.70M | $30.70M | $30.70M | $10.00M | $0 | – | – | – | – | – | 0.0% | -100.0% |
| KALYDECO | – | – | – | – | – | – | – | – | – | – | $475.50M | $499.20M | – | – |
| ORKAMBI | – | – | – | – | – | – | – | – | – | – | $326.00M | $392.60M | – | – |
| SYMDEKO/SYMKEVI | – | – | – | – | – | – | – | – | – | – | $123.00M | $129.50M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | $7.06B | $6.83B | $6.68B | $6.42B | $6.26B | $6.16B | $6.04B | $5.93B | – | – |
| Europe | – | – | – | – | $3.42B | $3.31B | $3.45B | $3.36B | $3.28B | $3.27B | $3.11B | $3.06B | – | – |
From the segment and revenue-disaggregation notes of Vertex Pharmaceuticals Inc / Ma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.